Chief Commercial Officer · Actinium Pharmaceuticals, Inc. (ATNM)

Anil Kapur

FY2018 is the first fiscal year CompBrief holds for Anil Kapur as a named executive officer of Actinium Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$505,663

Salary $294,402Stock awards $0

3rd of 6 named executive officers at Actinium Pharmaceuticals by FY2018 total.

6 named officers on file for Actinium Pharmaceuticals, FY2018

Anil Kapur’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Actinium Pharmaceuticals’s whole pay program stands against its peers

  • Actinium Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ATNM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed November 25, 2019 (DEF 14A).

Free

Get Anil Kapur’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Anil Kapur compensation by year

Actinium Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Actinium Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018
Salary$294,402
Bonus$0
Stock awards$0
Option awards$211,261
Non-equity incentive$0
Pension and deferred compensation$0
All other$0
Total$505,663

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Actinium Pharmaceuticals, Inc. DEF 14A filed November 25, 2019, accession 0001213900-19-024628, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Actinium Pharmaceuticals, Inc. filed document, accession 0001213900-19-024628. Every figure is read from that document and cited to the page and table it appears in. Filed November 25, 2019.

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option475,000—$0.64

Per the Outstanding Equity Awards at Fiscal Year-End table in Actinium Pharmaceuticals, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Actinium Pharmaceuticals’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Sandesh SethChairman and Chief Executive Officer$1,374,253
Mark BergerChief Medical Officer$612,313
Anil Kapur · this pageChief Commercial Officer$505,663
Steve O’LoughlinChief Financial Officer$505,552
Dale LudwigChief Scientific Officer$424,695
Nitya RayFormer Executive Vice President (5)$399,525

The full Actinium Pharmaceuticals compensation record

free company brief

This page is one person within Actinium Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Actinium Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Anil Kapur's compensation dossier · One-time report. No refunds.